Senate Finance Report Might Shed Light on Insulin Manufacturers’ 340B Contract Pharmacy Actions

HHS has for the second time delayed the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The new date is July 20. | Shutterstock

U.S. insulin manufacturer and pharmacy benefit manager (PBM) business practices “have created a vicious cycle of price increases that have sent costs for patients and taxpayers through the roof,” U.S. Senate Finance Committee leaders Chuck Grassley (R-Iowa) and Ron Wyden

Read More »

Azar and Verma Touch on 340B in Valedictory Remarks

Outgoing HHS Secretary Alex Azar (left) and CMS Administrator Seema Verma touched on 340B in farewell remarks.| Source: C-SPAN

Outgoing U.S. Health and Human Services (HHS) Secretary Alex Azar and Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma both referred to 340B—obliquely in Azar’s case, directly in Verma’s—in recent farewell remarks.

In an interview with Modern Healthcare

Read More »

340B Stakeholders Reconsider Campaign Contributions in Wake of Capitol Riot

Businesses and groups involved in 340B are reconsidering their political donations following a pro-Trump mob's assault on the U.S. Capitol. | Source: Shutterstock

National health care organizations and businesses with major stakes in the 340B program have suspended political contributions following a pro-Trump mob’s Jan. 6 violent attack on Congress to stop it from counting and certifying the Electoral College’s votes for president.

Read More »

Top 10 Issues to Consider in 2021

SPONSORED CONTENT by Jim Jorgenson, CEO, Visante

2020 was a year like no other! Dominated by challenges and uncertainty with the pandemic and the economy, and the political landscape overshadowing everything.

As always, and particularly in the face of rising challenges, we would like to thank our many clients for trusting us to support their organizations and to help them weather the storm as we head into what will hopefully be a better 2021.

As we look ahead, as

Read More »

Lilly Asks Court to Shield it From “Crippling” 340B Sanctions

Drug manufacturer Eli Lilly and Co. told a court this week that HHS has placed it in the "untenable position of offering 340B discounts that are not required by the statute or else facing crippling financial sanctions." | Source: Shutterstock

340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.

Read More »

AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies

AstraZeneca, Eli Lilly and Co., and Sanofi sued HHS in defense of their 340B contract actions just hours before covered entities could begin challenging those actions in a new 340B administrative dispute resolution process. | Source: Shutterstock

In a major escalation of the fight over 340B contract pharmacy, drug manufacturer AstraZeneca late yesterday asked a federal court to declare that it “is not required to offer 340B discounts to contract pharmacies.”

As we went to press, we

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report